keyword
MENU ▼
Read by QxMD icon Read
search

liver cancer trial

keyword
https://www.readbyqxmd.com/read/28922704/direct-acting-antivirals-for-chronic-hepatitis-c
#1
REVIEW
Janus C Jakobsen, Emil Eik Nielsen, Joshua Feinberg, Kiran Kumar Katakam, Kristina Fobian, Goran Hauser, Goran Poropat, Snezana Djurisic, Karl Heinz Weiss, Milica Bjelakovic, Goran Bjelakovic, Sarah Louise Klingenberg, Jian Ping Liu, Dimitrinka Nikolova, Ronald L Koretz, Christian Gluud
BACKGROUND: Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs), e.g. sofosbuvir, are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response). Sustained virological response (SVR) is used by investigators and regulatory agencies as a surrogate outcome for morbidity and mortality, based solely on observational evidence...
September 18, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28910150/phase-i-ii-trial-of-anticarcinoembryonic-antigen-radioimmunotherapy-gemcitabine-and-hepatic-arterial-infusion-of-fluorodeoxyuridine-postresection-of-liver-metastasis-for-colorectal-carcinoma
#2
Benjamin Cahan, Lucille Leong, Lawrence Wagman, David Yamauchi, Stephen Shibata, Sharon Wilzcynski, Lawrence E Williams, Paul Yazaki, David Colcher, Paul Frankel, Anna Wu, Andrew Raubitschek, John Shively, Jeffrey Y C Wong
OBJECTIVES: Report the feasibility, toxicities, and long-term results of a Phase I/II trial of (90)Y-labeled anticarcinoembryonic antigen (anti-CEA) (cT84.66) radioimmunotherapy (RIT), gemcitabine, and hepatic arterial infusion (HAI) of fluorodeoxyuridine (FUdR) after maximal hepatic resection of metastatic colorectal cancer to the liver. METHODS: Patients with metastatic colorectal cancer to the liver postresection or ablation to minimum disease were eligible. Each cohort received HAI of FUdR for 14 days on a dose escalation schedule...
September 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28906589/neoadjuvant-therapy-of-bevacizumab-in-combination-with-oxaliplatin-and-capecitabine-xelox-for-patients-with-metastatic-colorectal-cancer-with-unresectable-liver-metastases-a-phase-ii-open-label-single-arm-noncomparative-trial
#3
Hong-Hwa Chen, Jen-Kou Lin, Joe-Bin Chen, Chieh-Han Chuang, Mei-Ching Liu, Jen-Yi Wang, Chung-Rong Changchien
AIM: This phase II, open-label study evaluated the efficacy and safety of neoadjuvant therapy with bevacizumab plus XELOX (capecitabine and oxaliplatin) for untreated metastatic colorectal cancer with unresectable liver metastases and assessed conversion of unresectable to resectable metastases after neoadjuvant treatment. METHODS: Patients received bevacizumab 5 mg/kg and oxaliplatin 85 mg/m(2) on day 1, and capecitabine 1000 mg/m(2) twice daily on days 1-5 followed by 2 days of rest in a 14-day cycle for 12 cycles; bevacizumab was excluded in cycles 6 and 7...
September 14, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28903369/toxicology-and-efficacy-of-tumor-targeting-salmonella-typhimurium-a1-r-compared-to-vnp-20009-in-a-syngeneic-mouse-tumor-model-in-immunocompetent-mice
#4
Yong Zhang, Wenluo Cao, Makoto Toneri, Nan Zhang, Tasuku Kiyuna, Takashi Murakami, Scott D Nelson, Sarah M Dry, Yunfeng Li, Shukuan Li, Xiaoen Wang, Huaiyu Ma, Arun S Singh, Fritz C Eilber, Robert M Hoffman, Ming Zhao
Salmonella typhimurium A1-R (S. typhimurium A1-R) attenuated by leu and arg auxotrophy has been shown to target multiple types of cancer in mouse models. In the present study, toxicologic and biodistribution studies of tumor-targeting S. typhimurium A1-R and S. typhimurium VNP20009 (VNP 20009) were performed in a syngeneic tumor model growing in immunocompetent BALB/c mice. Single or multiple doses of S. typhimurium A1-R of 2.5 × 10(5) and 5 × 10(5) were tolerated. A single dose of 1 × 10(6) resulted in mouse death...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28902669/alpps-improves-resectability-compared-with-conventional-two-stage-hepatectomy-in-patients-with-advanced-colorectal-liver-metastasis-results-from-a-scandinavian-multicenter-randomized-controlled-trial-ligro-trial
#5
Per Sandström, Bård I Røsok, Ernesto Sparrelid, Peter N Larsen, Anna L Larsson, Gert Lindell, Nicolai A Schultz, Bjorn A Bjørnbeth, Bengt Isaksson, Magnus Rizell, Bergthor Björnsson
OBJECTIVE: The aim of the study was to evaluate if associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) could increase resection rates (RRs) compared with two-stage hepatectomy (TSH) in a randomized controlled trial (RCT). BACKGROUND: Radical liver metastasis resection offers the only chance of a cure for patients with metastatic colorectal cancer. Patients with colorectal liver metastasis (CRLM) and an insufficient future liver remnant (FLR) volume are traditionally treated with chemotherapy with portal vein embolization or ligation followed by hepatectomy (TSH)...
September 11, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28900326/the-relationship-between-serum-selenium-and-zinc-with-gastroesophageal-cancers-in-the-southeast-of-iran
#6
Seyed Mehdi Hashemi, Mohamadali Mashhadi, Alireza Ansari Moghaddam, Javad Yousefi, Ahmad Dizangian Mofrad, Masoud Sadeghi, Abolghasem Allahyari
BACKGROUND: Selenium (Se) and zinc (Zn) have antioxidant and anticancer properties. OBJECTIVE: The aim of this study was to evaluate the serum levels of Se and Zn and the correlation between the levels of these two elements with risk of incidence of esophageal cancer (EC) and gastric cancer (GC). MATERIALS AND METHODS: In a case-control study, we selected sixty patients with GC or EC as the intervention group and 120 age-matched individuals as the control group...
April 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/28895143/randomized-clinical-trial-of-laparoscopic-ultrasonography-before-laparoscopic-colorectal-cancer-resection
#7
S B Ellebaek, C W Fristrup, C Hovendal, N Qvist, L Bundgaard, S Salomon, J Støvring, M B Mortensen
BACKGROUND: Intraoperative ultrasonography during open surgery for colorectal cancer may be useful for the detection of unrecognized liver metastases. Laparoscopic ultrasonography (LUS) for the detection of unrecognized liver metastasis has not been studied in a randomized trial. This RCT tested the hypothesis that LUS would change the TNM stage and treatment strategy. METHODS: Patients with colorectal cancer and no known metastases were randomized (1 : 1) to laparoscopic examination (control or laparoscopy plus LUS) in three Danish centres...
October 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28894793/infiltrative-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-treated-with-a-single-high-dose-y90-radioembolization-and-subsequent-liver-transplantation-without-a-recurrence
#8
Meaghan S Dendy, Juan C Camacho, Johannes M Ludwig, Alyssa M Krasinskas, Stuart J Knechtle, Hyun S Kim
BACKGROUND: Infiltrative hepatocellular carcinoma with macrovascular invasion is a relatively rare presentation and usually fatal disease. METHODS: Both patients exceeded Milan and University of California-San Francisco (UCSF) criteria, and per Barcelona Clinic Liver Cancer group guidelines, they were enrolled in a prospective open-label radioembolization phase II trial that gave them optimized lobar doses of Yttrium-90 as solely the first-line therapy without concomitant or additional pharmacological or locoregional therapies...
September 2017: Transplantation Direct
https://www.readbyqxmd.com/read/28893935/tumour-virus-vaccines-hepatitis-b-virus-and-human-papillomavirus
#9
REVIEW
Margaret Stanley
Two of the most important human oncogenic viruses are hepatitis B virus (HBV) and human papillomavirus (HPV). HBV infection has been preventable by vaccination since 1982; vaccination of neonates and infants is highly effective, resulting already in decreased rates of new infections, chronic liver disease and hepato-cellular carcinoma. Nonetheless, HBV remains a global public health problem with high rates of vertical transmission from mother to child in some regions. Prophylactic HPV vaccines composed of virus-like particles (VLPs) of the L1 capsid protein have been licensed since 2006/2007...
October 19, 2017: Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
https://www.readbyqxmd.com/read/28891127/helicobacter-pylori-gastric-cancer-and-other-gastrointestinal-malignancies
#10
REVIEW
Marino Venerito, Riccardo Vasapolli, Theodore Rokkas, Jean-Charles Delchier, Peter Malfertheiner
In a retrospective study performed in California, U.S.A., ca. 3% of patients with gastric intestinal metaplasia (GIM) developed gastric cancer (GC) within a median time period of 4.6 years after diagnosis of GIM. This observation stresses the importance of targeted surveillance even in regions with a low GC prevalence. Patients with alcoholic liver disease as well as survivors of colorectal and lobular breast cancer were found to be at increased risk of secondary GC. A population-based Chinese study confirmed "serologic biopsy" as a useful screening tool for stratifying the individual risk of developing GC...
September 2017: Helicobacter
https://www.readbyqxmd.com/read/28890809/a-single-institute-retrospective-trial-of-concurrent-chemotherapy-with-sir-spheres-%C3%A2-versus-sir-spheres-%C3%A2-alone-in-chemotherapy-resistant-colorectal-cancer-liver-metastases
#11
May Cho, Jonathan Kessler, John J Park, Aram Lee, Jun Gong, Gagandeep Singh, Yi-Jen Chen, Philip H G Ituarte, Marwan Fakih
BACKGROUND: The use of selective internal radiation therapy with yttrium 90 resin microspheres (SIR-Spheres(®)) in chemotherapy-resistant colorectal cancer liver metastases has been associated with favorable progression-free survival (PFS) and overall survival when given alone or concurrently with chemotherapy. We conducted a single institute retrospective trial to explore the potential impact of SIR-Spheres(®) with concurrent chemotherapy vs. SIR-Spheres(®) alone on liver PFS in patients with colorectal liver metastases (CRLM)...
August 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28882451/development-and-mechanism-of-small-activating-rna-targeting-cebpa-a-novel-therapeutic-in-clinical-trials-for-liver-cancer
#12
Jon Voutila, Vikash Reebye, Thomas C Roberts, Pantelitsa Protopapa, Pinelopi Andrikakou, David C Blakey, Robert Habib, Hans Huber, Pal Saetrom, John J Rossi, Nagy A Habib
Small activating RNAs (saRNAs) are short double-stranded oligonucleotides that selectively increase gene transcription. Here, we describe the development of an saRNA that upregulates the transcription factor CCATT/enhancer binding protein alpha (CEBPA), investigate its mode of action, and describe its development into a clinical candidate. A bioinformatically directed nucleotide walk around the CEBPA gene identified an saRNA sequence that upregulates CEBPA mRNA 2.5-fold in human hepatocellular carcinoma cells...
August 4, 2017: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/28881688/the-clinical-utility-and-outcomes-of-microwave-ablation-for-colorectal-cancer-liver-metastases
#13
Pengyuan Song, Lijun Sheng, Yahong Sun, Yuji An, Ya Guo, Yafei Zhang
In recent years, the microwave ablation (MWA) has been reported to play an important role in the treatment of patients with colorectal liver metastases (CRLM). In this work, 62 cases of patients who received MWA for liver metastases from colon or rectal cancer between Jan 2012 and Jan 2014 were enrolled in this trial. 28 underwent MWA, and 34 were treated with liver resection as control. Perioperative and 60 months of follow-up data were collected to analyze potential adverse effects, concurrent conditions and survival status...
August 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28880439/complete-response-in-a-patient-with-stage-iv-adrenocortical-carcinoma-treated-with-adjuvant-trans-catheter-arterial-chemo-embolization-tace
#14
Eugene Wong, Sarah Jacques, Michael Bennett, Vineet Gorolay, Adrian Lee, Stephen Clarke
Adrenocortical carcinoma is a rare cancer, with estimate population incidence of 0.7-2.0 cases per 1 million each year. It also carries poor prognosis with estimated 5-year survival of less than 15% of those with metastatic disease and has a poor response to cytotoxic treatment. A randomized controlled trial published in 2012 by Fassnacht et al. demonstrated improved progression-free survival with first-line etoposide-doxirubicin-cisplatin-mitotane (EDP-M) compared to first-line streptozocin-mitotane in patients with stage III-IV disease...
September 6, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28879168/the-oncopig-cancer-model-an-innovative-large-animal-translational-oncology-platform
#15
REVIEW
Kyle M Schachtschneider, Regina M Schwind, Jordan Newson, Nickolas Kinachtchouk, Mark Rizko, Nasya Mendoza-Elias, Paul Grippo, Daniel R Principe, Alex Park, Nana H Overgaard, Gregers Jungersen, Kelly D Garcia, Ajay V Maker, Laurie A Rund, Howard Ozer, Ron C Gaba, Lawrence B Schook
Despite an improved understanding of cancer molecular biology, immune landscapes, and advancements in cytotoxic, biologic, and immunologic anti-cancer therapeutics, cancer remains a leading cause of death worldwide. More than 8.2 million deaths were attributed to cancer in 2012, and it is anticipated that cancer incidence will continue to rise, with 19.3 million cases expected by 2025. The development and investigation of new diagnostic modalities and innovative therapeutic tools is critical for reducing the global cancer burden...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28870611/safety-and-activity-of-microrna-loaded-minicells-in-patients-with-recurrent-malignant-pleural-mesothelioma-a-first-in-man-phase-1-open-label-dose-escalation-study
#16
Nico van Zandwijk, Nick Pavlakis, Steven C Kao, Anthony Linton, Michael J Boyer, Stephen Clarke, Yennie Huynh, Agata Chrzanowska, Michael J Fulham, Dale L Bailey, Wendy A Cooper, Leonard Kritharides, Lloyd Ridley, Scott T Pattison, Jennifer MacDiarmid, Himanshu Brahmbhatt, Glen Reid
BACKGROUND: TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with miR-16-based mimic microRNA (miRNA) and targeted to EGFR that are designed to counteract the loss of the miR-15 and miR-16 family miRNAs, which is associated with unsuppressed tumour growth in preclinical models of malignant pleural mesothelioma. We aimed to assess the safety, optimal dosing, and activity of TargomiRs in patients with malignant pleural mesothelioma. METHODS: In this first-in-man, open-label, dose-escalation phase 1 trial at three major cancer centres in Sydney (NSW, Australia), we recruited adults (aged ≥18 years) with a confirmed diagnosis of malignant pleural mesothelioma, measurable disease, radiological signs of progression after previous chemotherapy, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of 3 months or more, immunohistochemical evidence of tumour EGFR expression, and adequate bone marrow, liver, and renal function...
September 1, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28859185/salvage-chemoimmunotherapy-with-inotuzumab-ozogamicin-combined-with-mini-hyper-cvd-for-patients-with-relapsed-or-refractory-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia-a-phase-2-clinical-trial
#17
Elias Jabbour, Farhad Ravandi, Partow Kebriaei, Xuelin Huang, Nicholas J Short, Deborah Thomas, Koji Sasaki, Michael Rytting, Nitin Jain, Marina Konopleva, Guillermo Garcia-Manero, Richard Champlin, David Marin, Tapan Kadia, Jorge Cortes, Zeev Estrov, Koichi Takahashi, Yogin Patel, Maria R Khouri, Jovitta Jacob, Rebecca Garris, Susan O'Brien, Hagop Kantarjian
Importance: The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has single-agent activity in R/R ALL. Objective: To evaluate the efficacy and safety of inotuzumab ozogamicin plus low-intensity chemotherapy in patients with R/R ALL. Design, Setting, and Participants: A single-arm, phase 2 study of adults with R/R B-cell ALL conducted at The University of Texas MD Anderson Cancer Center, Houston...
August 31, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28854942/the-biology-of-hepatocellular-carcinoma-implications-for-genomic-and-immune-therapies
#18
REVIEW
Galina Khemlina, Sadakatsu Ikeda, Razelle Kurzrock
Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is a leading cause of cancer-related death worldwide. It is highly refractory to most systemic therapies. Recently, significant progress has been made in uncovering genomic alterations in HCC, including potentially targetable aberrations. The most common molecular anomalies in this malignancy are mutations in the TERT promoter, TP53, CTNNB1, AXIN1, ARID1A, CDKN2A and CCND1 genes. PTEN loss at the protein level is also frequent. Genomic portfolios stratify by risk factors as follows: (i) CTNNB1 with alcoholic cirrhosis; and (ii) TP53 with hepatitis B virus-induced cirrhosis...
August 30, 2017: Molecular Cancer
https://www.readbyqxmd.com/read/28852974/low-dose-versus-standard-dose-of-corticosteroids-in-the-management-of-adverse-events-of-special-interest-from-abiraterone-acetate-data-from-a-literature-based-meta-analysis
#19
Giandomenico Roviello, Silvia Paola Corona, Daniele Generali
Abiraterone acetate is a CYP-17 inhibitor approved for the treatment of prostate cancer. Abiraterone acetate (AA) therapy is associated with toxicities, including hypokalemia, hypertension, liver function test abnormalities and cardiac events. These adverse events are traditionally managed with a standard dose of corticosteroids. However, preliminary data are available on the use of a lower dose of corticosteroids. The aim of this report is to perform a pooled analysis evaluating the risk ratio (RR) of AA-related adverse events of special interest associated with low or standard dose of corticosteroids...
August 29, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28846876/inhalation-delivery-of-complex-drugs-the-next-steps
#20
REVIEW
Wilbur de Kruijf, Carsten Ehrhardt
Oral inhalation offers the opportunity of targeting drugs locally to different regions of the respiratory tract or alternatively, using the high surface area of the alveoli for systemic delivery. Pulmozyme and the inhaled insulins (i.e. Exubera and Afrezza) are examples of the scope of pulmonary drug delivery of biopharmaceuticals-albeit with strikingly different commercial success. Particularly, the failure of Exubera and the subsequent overreactions (e.g. the unsubstantiated lung cancer fear), lastingly stunned the field of systemically inhaled protein and peptide drugs...
August 25, 2017: Current Opinion in Pharmacology
keyword
keyword
28816
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"